Pfizer, Abbott, Others Hit With False Marking Suits

Law360, New York (July 19, 2010, 5:21 PM EDT) -- Promote Innovation LLC has launched four qui tam actions accusing several drugmakers — including Pfizer Inc., Abbott Laboratories Inc, Bayer Healthcare Pharmaceuticals Inc., Schering Corp., Merck & Co. Inc. and Celgene Corp. — of falsely marking their products with expired patents.

The complaints, filed Friday in the U.S. District Court for the Eastern District of Texas, claim that the drugmakers have marked diabetes drug Glyset, hormone treatment Lupron, lymphoma drug Istodax and allergy treatment Clarinex with at least one expired patent in violation of the federal...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.